Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway

Liu,Xia; Peng,Jiamin; Zhou,Yayun; Xie,Bei; Wang,Jianchao

doi:10.3892/mmr.2019.10465

Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway

Authors:
- Xia Liu
- Jiamin Peng
- Yayun Zhou
- Bei Xie
- Jianchao Wang
View Affiliations

Affiliations: Central Laboratory, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China, Department of Clinical Laboratory, Zhejiang Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China
Published online on: July 3, 2019 https://doi.org/10.3892/mmr.2019.10465
Pages: 2159-2166
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ribonucleotide reductase M2 (RRM2) is one of the two subunits that comprise ribonucleotide reductase (RR), the enzyme that catalyzes the conversion of ribonucleotide 5'‑diphosphates into 2'‑deoxyribonucleotides, which are required for DNA synthesis. RRM2 is a stress response factor important for the development of several tumors. However, its role in multiple myeloma (MM) remains to be fully elucidated. The present study aimed to investigate the role of RRM2 in MM. The expression of RRM2 in patients with MM was analyzed using the Oncomine database. The results demonstrated that RRM2 expression was higher in MM compared with healthy subjects. Reverse transcription‑quantitative polymerase chain reaction and western blot results revealed that RRM2 expression was decreased following transfection with a small interfering RNA targeting RRM2 into NCI‑H929 cells. RR activity and Cell Counting Kit‑8 assays demonstrated that RRM2 silencing reduced RR activity and inhibited cell proliferation. Annexin V‑propidium iodide staining indicated that the percentage of apoptotic NCI‑H929 cells was increased following RRM2 silencing compared with that in the control group. Increased phosphorylation of H2AX indicated that RRM2 silencing may activate the DNA‑damage response pathway in NCI‑H929 cells. Western blot analysis revealed that protein levels of the apoptosis‑associated factor Bcl‑2 were reduced, whereas Bax, cleaved caspase‑3 and cleaved poly(ADP‑ribose) polymerase 1 were upregulated following RRM2 silencing compared with the control group. In addition, the results demonstrated that RRM2 silencing may inhibit target gene expression in the Wnt/β‑catenin signaling pathway by increasing the phosphorylation of glucose synthase kinase 3β. These findings indicated that RRM2 may be involved in the proliferation and apoptosis of MM cells via the Wnt/β‑catenin signaling pathway, suggesting that RRM2 may represent a novel therapeutic target for MM.

View Figures

View References

1	Becker N: Epidemiology of multiple myeloma. Recent Results Cancer Res. 183:25–35. 2011. View Article : Google Scholar : PubMed/NCBI
2	Martin T and Huff CA: Multiple myeloma: Current advances and future directions. Clin Lymphoma Myeloma Leuk. 19:255–263. 2019. View Article : Google Scholar : PubMed/NCBI
3	Howlader N NA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER Cancer Statistics Review, 1975–2013, National Cancer Institute Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER website, 2016. https://seer.cancer.gov/archive/csr/1975_2013/April 20–2016
4	Cid Ruzafa J, Merinopoulou E, Baggaley RF, Leighton P, Werther W, Felici D and Cox A: Patient population with multiple myeloma and transitions across different lines of therapy in the USA: An epidemiologic model. Pharmacoepidemiol Drug Saf. 25:871–879. 2016. View Article : Google Scholar : PubMed/NCBI
5	Varga C, Maglio M, Ghobrial IM and Richardson PG: Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 181:447–459. 2018. View Article : Google Scholar : PubMed/NCBI
6	Crona M, Codó P, Jonna VR, Hofer A, Fernandes AP and Tholander F: A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity. Mol Oncol. 10:1375–1386. 2016. View Article : Google Scholar : PubMed/NCBI
7	Aye Y, Li M, Long MJ and Weiss RS: Ribonucleotide reductase and cancer: Biological mechanisms and targeted therapies. Oncogene. 34:2011–2021. 2015. View Article : Google Scholar : PubMed/NCBI
8	Shao J, Liu X, Zhu L and Yen Y: Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets. 17:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
9	Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010. View Article : Google Scholar : PubMed/NCBI
10	Morikawa T, Maeda D, Kume H, Homma Y and Fukayama M: Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wang L, Meng L, Wang XW, Ma GY and Chen JH: Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
12	D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, Saraf A, Florens L, Washburn MP and Pagano M: Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 149:1023–1034. 2012. View Article : Google Scholar : PubMed/NCBI
13	Dai L, Lin Z, Qiao J, Chen Y, Flemington EK and Qin Z: Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene. 36:5068–5074. 2017. View Article : Google Scholar : PubMed/NCBI
14	Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y, Sin FM, Yeung S, Cheng AS, Yu J and To K: Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep. 31:2579–2586. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang N, Li Y and Zhou J: Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells. Oncol Lett. 15:3719–3725. 2018.PubMed/NCBI
16	Shah KN, Wilson EA, Malla R, Elford HL and Faridi JS: Targeting ribonucleotide reductase M2 and NF-κB activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther. 14:2411–2421. 2015. View Article : Google Scholar : PubMed/NCBI
17	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
18	Lin ZP, Belcourt MF, Cory JG and Sartorelli AC: Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(−/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem. 279:27030–27038. 2004. View Article : Google Scholar : PubMed/NCBI
19	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004. View Article : Google Scholar : PubMed/NCBI
20	Huang P, Yan R, Zhang X, Wang L, Ke X and Qu Y: Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities. Pharmacol Ther. 196:79–90. 2019. View Article : Google Scholar : PubMed/NCBI
21	van Andel H, Kocemba KA, Spaargaren M and Pals ST: Aberrant Wnt signaling in multiple myeloma: Molecular mechanisms and targeting options. Leukemia. 33:1063–1075. 2019. View Article : Google Scholar : PubMed/NCBI
22	Zhu L, Zhou B, Chen X, Jiang H, Shao J and Yen Y: Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase. Biochem Pharmacol. 78:1178–1185. 2009. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S and Neri A: The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 17:7402–7412. 2011. View Article : Google Scholar : PubMed/NCBI
25	Furukawa Y and Kikuchi J: Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 20:413–422. 2015. View Article : Google Scholar : PubMed/NCBI
26	Mimura N, Hideshima T and Anderson KC: Novel therapeutic strategies for multiple myeloma. Exp Hematol. 43:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
27	Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G and Song L: Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy. Oncol Rep. 40:355–360. 2018.PubMed/NCBI
28	Li C, Zheng J, Chen S, Huang B, Li G, Feng Z, Wang J and Xu S: RRM2 promotes the progression of human glioblastoma. J Cell Physiol. 233:6759–6767. 2018. View Article : Google Scholar : PubMed/NCBI
29	Mannarqudi MB and Deb S: Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: Is it a viable cancer therapy? J Cancer Res Clin Oncol. 143:1499–1529. 2017. View Article : Google Scholar : PubMed/NCBI
30	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
31	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
32	Mahler M, Miyachi K, Peebles C and Fritzler MJ: The clinical signifcance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev. 11:771–775. 2012. View Article : Google Scholar : PubMed/NCBI
33	Solier S and Pommier Y: The nuclear γ-H2AX apoptotic ring: Implications for cancers and autoimmune diseases. Cell Mol Life Sci. 71:2289–2297. 2014. View Article : Google Scholar : PubMed/NCBI
34	Khalilzadeh B, Shadjou N, Kanberoglu GS, Afsharan H, de la Guardia M, Charoudeh HN, Ostadrahimi A and Rashidi MR: Advances in nanomaterial based optical biosensing and bioimaging of apoptosis via caspase-3 activity: A review. Mikrochim Acta. 185:4342018. View Article : Google Scholar : PubMed/NCBI
35	Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J and Boothman DA: Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 24:15–28. 2014. View Article : Google Scholar : PubMed/NCBI
36	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
37	Tammela T, Sanchez-Rivera FJ, Centinbas NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft RA, et al: A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 545:355–359. 2017. View Article : Google Scholar : PubMed/NCBI
38	Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M and Pals ST: Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood. 131:982–994. 2018. View Article : Google Scholar : PubMed/NCBI